LoginSignup
Viking Therapeutics logo

Viking Therapeutics

Stock
Stock
ISIN: US92686J1060
Ticker: VKTX
US92686J1060
VKTX

Price

Price

Frequently asked questions

What is Viking Therapeutics's market capitalization?

The market capitalization of Viking Therapeutics is $5.75B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Viking Therapeutics?

Viking Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.937. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Viking Therapeutics's stock?

Currently, 11 analysts cover Viking Therapeutics's stock, with a consensus target price of $114.20. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Viking Therapeutics?

Viking Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$133.97M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Viking Therapeutics?

Viking Therapeutics has a free cash flow of -$74.25M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Viking Therapeutics's stock?

The 5-year beta for Viking Therapeutics is 0.91. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Viking Therapeutics have, and what sector and industry does it belong to?

Viking Therapeutics employs approximately 33 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Viking Therapeutics's shares?

The free float of Viking Therapeutics is 103.09M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $5.75B

5Y beta

 0.91

EPS (TTM)

 -$0.937

Free Float

 103.09M

EBITDA (TTM)

 -$133.97M

Free Cashflow (TTM)

 -$74.25M

Pricing

1D span
$52.00$54.03
52W span
$11.55$99.41

Analyst Ratings

The price target is $114.20 and the stock is covered by 11 analysts.

Buy

11

Hold

0

Sell

0

Information

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

33

Biotechnology & Drugs

Health Care

Identifier

ISIN

US92686J1060

Primary Ticker

VKTX

Knockouts

Join the conversation
Sign upLogin